Bio Rad Laboratories Inc
NYSE:BIO

Watchlist Manager
Bio Rad Laboratories Inc Logo
Bio Rad Laboratories Inc
NYSE:BIO
Watchlist
Price: 332.91 USD 2.25% Market Closed
Market Cap: 9.3B USD
Have any thoughts about
Bio Rad Laboratories Inc?
Write Note

Gross Margin
Bio Rad Laboratories Inc

54.4%
Current
55%
Average
43.8%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
54.4%
=
Gross Profit
1.4B
/
Revenue
2.6B

Gross Margin Across Competitors

Country US
Market Cap 9.3B USD
Gross Margin
54%
Country US
Market Cap 1.3T USD
Gross Margin
55%
Country US
Market Cap 196.3B USD
Gross Margin
41%
Country US
Market Cap 170.3B USD
Gross Margin
60%
Country KR
Market Cap 66.5T KRW
Gross Margin
50%
Country CH
Market Cap 37.6B CHF
Gross Margin
29%
Country US
Market Cap 38.5B USD
Gross Margin
55%
Country US
Market Cap 36.7B USD
Gross Margin
35%
Country US
Market Cap 26.4B USD
Gross Margin
59%
Country US
Market Cap 23B USD
Gross Margin
35%
Country US
Market Cap 22.3B USD
Gross Margin
64%
No Stocks Found

Bio Rad Laboratories Inc
Glance View

Market Cap
9.3B USD
Industry
Life Sciences Tools & Services

Bio-Rad Laboratories Inc. is a global leader in the life sciences and clinical diagnostics industries, renowned for its innovative technologies that empower researchers and healthcare professionals. Founded in 1952, Bio-Rad has developed a diverse portfolio of products that serve a wide range of applications, from advancing scientific research in genomics and proteomics to enhancing diagnostic capabilities in clinical laboratories. The company operates through two key segments: Life Science and Diagnostics, which together create synergies that drive growth. With a commitment to quality and customer satisfaction, Bio-Rad has built a reputation for reliability and technical excellence, making it a trusted partner in the quest for scientific breakthroughs and improved patient care. Investors looking at Bio-Rad will find a resilient company with strong fundamentals and a consistent track record of performance. The firm benefits from ongoing trends in healthcare and biotechnology, with increasing demand for precision medicine and advanced molecular diagnostics leading to robust revenue streams. Bio-Rad's global footprint and extensive distribution network not only mitigate risks associated with market fluctuations but also position the company to capitalize on emerging technologies and expanding international markets. With a strategic focus on innovation and a history of prudent financial management, Bio-Rad Laboratories offers investors an opportunity to be part of a company that is at the forefront of scientific advancement while also delivering solid returns.

BIO Intrinsic Value
376.25 USD
Undervaluation 12%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
54.4%
=
Gross Profit
1.4B
/
Revenue
2.6B
What is the Gross Margin of Bio Rad Laboratories Inc?

Based on Bio Rad Laboratories Inc's most recent financial statements, the company has Gross Margin of 54.4%.